Literature DB >> 10938273

Identification of the elements regulating the expression of the cell adhesion molecule MCAM/MUC18. Loss of AP-2 is not required for MCAM expression in melanoma cell lines.

C S Mintz-Weber1, J P Johnson.   

Abstract

The cell adhesion molecule melonoma cell adhesion molecule (MCAM)/MUC18/CD146 is specifically up-regulated on tumors of neuroectodermal origin and in animal models confers metastatic capacity to human melanoma cells. To identify critical regions regulating MCAM expression in melanomas, 1 kilobase of the MCAM 5' region was analyzed for promoter activity and transcription factor binding in 1 glioma, 1 carcinoma, and 4 melanoma cell lines. The minimal MCAM promoter (-106/+22 base pair (bp)) consists of 4 Sp-1 sites, two AP-2 elements, one cAMP responsive element, and the initiator surrounding the transcriptional start site. Analysis of mutated constructs indicated that the cAMP-responsive element is a major transcriptional activator in the majority of cell lines. Site-directed mutagenesis revealed that, in AP-2 expressing cells, the AP-2 site within the core promoter (-23 bp) has an inhibitory influence on MCAM expression while the AP-2 sites at -131 and -302 bp are activating. Functional AP-2 was observed in both MCAM positive and MCAM negative melanoma cell lines indicating that expression of MCAM does not require loss of this transcription factor. Furthermore, all MCAM constructs were strongly expressed in MCAM negative as well as MCAM positive cells, indicating that the expression of this gene is not controlled solely by the presence of transactivating factors binding to the investigated region.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938273     DOI: 10.1074/jbc.M003812200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Authors:  Vladislava O Melnikova; Krishnakumar Balasubramanian; Gabriel J Villares; Andrey S Dobroff; Maya Zigler; Hua Wang; Frederik Petersson; Janet E Price; Alan Schroit; Victor G Prieto; Mien-Chie Hung; Menashe Bar-Eli
Journal:  J Biol Chem       Date:  2009-08-24       Impact factor: 5.157

2.  Non-thermal atmospheric pressure plasmas as a novel candidate for preventive therapy of melanoma.

Authors:  Yasuhiro Omata; Machiko Iida; Ichiro Yajima; Kozue Takeda; Nobutaka Ohgami; Masaru Hori; Masashi Kato
Journal:  Environ Health Prev Med       Date:  2014-07-19       Impact factor: 3.674

3.  Expression and distribution of MUC18 in human uveal melanoma.

Authors:  Kenneth Lai; Vidushi Sharma; Martine J Jager; R Max Conway; Michele C Madigan
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

Review 4.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

5.  Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma.

Authors:  Belma Kocer; John McKolanis; Atilla Soran
Journal:  BMC Gastroenterol       Date:  2006-01-12       Impact factor: 3.067

Review 6.  Role of Biomarkers in the Integrated Management of Melanoma.

Authors:  Piyu Parth Naik
Journal:  Dis Markers       Date:  2021-12-30       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.